Literature DB >> 17968923

The widening mortality gap between rheumatoid arthritis patients and the general population.

Angel Gonzalez1, Hilal Maradit Kremers, Cynthia S Crowson, Paulo J Nicola, John M Davis, Terry M Therneau, Veronique L Roger, Sherine E Gabriel.   

Abstract

OBJECTIVE: Overall mortality rates in the general US population have declined substantially over the last 4-5 decades, but it is unclear whether patients with rheumatoid arthritis (RA) have experienced the same improvements in survival. The purpose of this study was to determine the mortality trends among RA patients compared with those in the general population.
METHODS: A population-based incidence cohort of RA patients was assembled, comprising all residents of Rochester, Minnesota ages > or = 18 years in whom RA was first diagnosed (according to the American College of Rheumatology [formerly, the American Rheumatism Association] 1987 criteria) between 1955 and 1995 and all residents of Olmsted County, Minnesota in whom RA was first diagnosed between 1995 and 2000. The patients were followed up longitudinally through their complete (inpatient and outpatient) medical records until death or January 1, 2007. Expected mortality was estimated from the National Center for Health Statistics life tables on the white population in Minnesota, using person-year methods. Poisson regression was used to model the observed mortality rates, adjusting for age, sex, and disease duration.
RESULTS: A cohort of 822 RA patients (72% women, mean age at RA incidence 58 years) was followed up for a median of 11.7 years, during which 445 of the RA patients died. Between 1965 and 2005, the mortality rates across the calendar years for female and male RA patients were relatively constant at 2.4 and 2.5 per 100 person-years, respectively. In contrast, the expected mortality rate in the Minnesota white population decreased substantially over the same time period in both sexes. Mortality in the female general population declined from 1.0 per 100 person-years in 1965 to 0.2 per 100 person-years in 2000. Mortality in the male general population decreased from 1.2 per 100 person-years in 1965 to 0.3 per 100 person-years in 2000. Therefore, the difference between the observed and expected mortality rates increased in more recent years, resulting in a widening of the mortality gap.
CONCLUSION: Our findings show that RA patients have not experienced improvements in survival over the past 4 decades, despite dramatic improvements in the overall rates of mortality in the general US population. Further research into the causes of the widening gap in mortality between RA patients and the general population, and the influence of current therapeutic strategies on mortality, is needed in order to develop strategies to reduce the excess mortality observed in RA patients.

Entities:  

Mesh:

Year:  2007        PMID: 17968923     DOI: 10.1002/art.22979

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  104 in total

Review 1.  Epidemiology of rheumatoid arthritis: rheumatoid arthritis and mortality.

Authors:  Elena Myasoedova; John M Davis; Cynthia S Crowson; Sherine E Gabriel
Journal:  Curr Rheumatol Rep       Date:  2010-10       Impact factor: 4.592

2.  Rheumatoid Arthritis and Mortality Among Women During 36 Years of Prospective Follow-Up: Results From the Nurses' Health Study.

Authors:  Jeffrey A Sparks; Shun-Chiao Chang; Katherine P Liao; Bing Lu; Alexander R Fine; Daniel H Solomon; Karen H Costenbader; Elizabeth W Karlson
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-06       Impact factor: 4.794

Review 3.  Atherosclerotic vascular disease in the autoimmune rheumatologic patient.

Authors:  Rekha Mankad
Journal:  Curr Atheroscler Rep       Date:  2015-04       Impact factor: 5.113

Review 4.  Cardiovascular comorbidity in rheumatic diseases: a focus on heart failure.

Authors:  Kerry Wright; Cynthia S Crowson; Sherine E Gabriel
Journal:  Heart Fail Clin       Date:  2014-01-10       Impact factor: 3.179

5.  Exploration of 3,6-dihydroimidazo(4,5-d)pyrrolo(2,3-b)pyridin-2(1H)-one derivatives as JAK inhibitors using various in silico techniques.

Authors:  Radhakrishnan S Jisha; Lilly Aswathy; Vijay H Masand; Jayant M Gajbhiye; Indira G Shibi
Journal:  In Silico Pharmacol       Date:  2017-10-12

6.  Myocardial Inflammation, Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography With Computed Tomography, Is Associated With Disease Activity in Rheumatoid Arthritis.

Authors:  Isabelle Amigues; Aylin Tugcu; Cesare Russo; Jon T Giles; Rachelle Morgenstein; Afshin Zartoshti; Christian Schulze; Raul Flores; Sabahat Bokhari; Joan M Bathon
Journal:  Arthritis Rheumatol       Date:  2019-02-28       Impact factor: 10.995

7.  Impact of rheumatoid arthritis on receiving a diagnosis of hypertension among patients with regular primary care.

Authors:  Christie M Bartels; Heather Johnson; Katya Voelker; Carolyn Thorpe; Patrick McBride; Elizabeth A Jacobs; Nancy Pandhi; Maureen Smith
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-09       Impact factor: 4.794

Review 8.  Biologics and heart failure in rheumatoid arthritis: are we any wiser?

Authors:  Maria I Danila; Nivedita M Patkar; Jeffrey R Curtis; Kenneth G Saag; Gim Gee Teng
Journal:  Curr Opin Rheumatol       Date:  2008-05       Impact factor: 5.006

Review 9.  Co-morbidity index in rheumatoid arthritis: time to think.

Authors:  Yasser El Miedany
Journal:  Clin Rheumatol       Date:  2015-10-26       Impact factor: 2.980

10.  Association between anti-TNF-α therapy and all-cause mortality.

Authors:  Lisa J Herrinton; Liyan Liu; Lang Chen; Leslie R Harrold; Marsha A Raebel; Jeffrey R Curtis; Marie R Griffin; Daniel H Solomon; Kenneth G Saag; James D Lewis
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-10-15       Impact factor: 2.890

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.